IPW

Docket No.: 066821-0267 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Reed, John C., et al.	Customer No.: 41552
Appl. No.	:	10/766,682	Confirmation No.: 2878
Filed	:	January 27, 2004	
Title	:	CARD3X-2 POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE	
Grp./A.U.	:	1634	
Examiner:	:	TO BE ASSIGNED	

CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 3, 2005.

Kate Lane

Kate Lane

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

Also attached: 1 Information Disclosure Listing of Reference
0 References

The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP

Matthew V. Grumbling
Registration No. 44,427

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 MVG:kml
Facsimile: 858.597.1585
Date: February 3, 2005

Docket No.: 066821-0267 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Reed, John C., et al.	Customer No.: 41552
Appl. No.	:	10/766,682	Confirmation No.: 2878
Filed	:	January 27, 2004	
Title	:	CARD3X-2 POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE	
Grp./A.U.	:	1634	
Examiner:	:	TO BE ASSIGNED	

CERTIFICATE OF MAILING (37 CFR. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Feb 3, 2005.

Kate Lane

Kate Lane

INFORMATION DISCLOSURE STATEMENT

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

The references were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 09/864,921, filed May 23, 2001, which is relied upon for an earlier filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR 1.98(d).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Matthew V. Grumbling
Registration No. 44,427

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
Phone: 858.535.9001 MVG:kml
Facsimile: 858.597.1585
Date: February 3, 2005

Please recognize our Customer No. 41552 as our correspondence address.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO.	SERIAL NO.
066821-0267	**10/766,682**
APPLICANT: **Reed, John C., et al.**	
FILING DATE: **January 27, 2004**	GROUP: **1634**

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US	5,223,409	06-29-1993	LADNER et al.	
		US				
		US				
		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code3-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes	Translation No
	2	WO 96/12016	04-25-96				
	3	WO 99/40102	08-12-99				
	4	WO99/40102 (corrected)	08-12-99				
	5	WO 01/00826	01-04-01				
	6	WO 01/18042	03-15-01				
	7	WO 01/30971	05-03-01				
	8	WO 01/66690	09-13-01				
	9	WO 01/72822	10-04-01				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	10	AHMAD et al., "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP," Cancer Res. 57:615-619 (1997)	
	11	ALTSCHUL et al., "Gapped Blast and PSI-Blast: a new generation of protein database search programs," Nucleic Acids Res. 25:3389-3402 (1997)	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

References were cited in previous application no.: 09/864,921

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. **066821-0267**	SERIAL NO. **10/766,682**
	APPLICANT **Reed, John C., et al.**	
	FILING DATE **January 27, 2004**	GROUP **1634**

	12	BERTIN et al., "Human CARD4 Protein is a Novel CED-4/Apaf-1 Cell Death Family Member that Activates NF-kB," J. Biol. Chem. 274:12955-12958 (1999)	
	13	DAMIANO et al., "CLAN, a Novel Human CED-4-like Gene," Genomics 75:77-83(2001)	
	14	DIDONATO et al., "A cytokine-responsive IkB kinase that activates the transcription factor NF-kB," Nature 388:548-554 (1997)	
	15	DUJON et al., The yeast genome project: what did we learn? Trends in Genetics 12(7):263-270 (1996)	
	16	ELLERBY et al., "Anti-cancer activity of targeted pro-apoptotic peptides," Nature Med. 5:1032-1038 (1999)	
	17	FLETCHER et al., "A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo," J. Interferon Cytokine Res. 15:243-248 (1995)	
	18	GEDDES et al., "Human CARD12 Is a Novel CED4/Apaf-1 Family Member That Induces Apoptosis," Biochemical and Biophysical Research Communications 284:77-82 (2001)	
	19	GREGORIADIS, Liposome Technology, Vols. I to III, 2nded., CRC Press, Boca Raton FL (1993). (Table of contents only)	
	20	HOFMANN et al., "The CARD domain: a new apoptotic signalling motif," Trends Biochem. Sci. 22:155-156 (1997)	
	21	HOLINGER et al., "Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases," J. Biol. Chem. 274:13298-13304 (1999)	
	22	INOHARA et al., "Nod1, an Apaf-1-like Activator of Caspase-9 and Nuclear Factor-kB," J. Biol. Chem. 274:14560-14567 (1999)	
	23	KOBE et al., "Proteins with leucine-rich repeats," Current Opinion in Structural Biology 3(5):409-416 (1995)	
	24	KOONIN et al., "The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation," TIBS 25(5):223-224 (2000)	
	25	LI et al., "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascase," Cell 91:479-489 (1997)	
	26	NEUFELD et al., "The Drosophila peanut Gene Is Required for Cytokinesis and Encodes a Protein Similar to Yeast Putative Bud Neck Filament Proteins," Cell 77:371-379 (1994)	
	27	OGURA et al., "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kB," J. of Biol. Chem. 276 (7):4812-4818 (2001)	
	28	POYET et al., "Identification of Ipaf, a Human Caspase-1-activating Protein Related to Apaf-1," Journal of Biological Chemistry 276:28309-28313 (2001)	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
References were cited in previous application no.: 09/864,921

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. **066821-0267**	SERIAL NO. **10/766,682**
	APPLICANT **Reed, John C., et al.**	
	FILING DATE **January 27, 2004**	GROUP **1634**

	29	RANO et al., "A combinatorial approach for determining protease specificities: application to interleukin-1 beta converting enzyme (ICE)," Chem. Biol. 4:149-155 (1997)	
	30	RODRIGUEZ et al., "Dark is a Drosophila homologue of Apaf-1/CED-4 and functions in an evolutionarily conserved death pathway," Nature Cell Biol. 1:272-279 (1999)	
	31	ROST et al., "Enzyme function less conserved than anticipated," Journal of Molecular Biology 318:595-609 (2002)	
	32	ROTHE et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins," Cell 83:1243-1252 (1995)	
	33	ROTONDA et al., "The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis," Nature Struc. Biol. 3:619-625 (1996)	
	34	RYCHLEWSKI et al., "Comparison of sequence profiles. Strategies for structural predictions using sequence information," Protein Science 9:232-241 (2000)	
	35	SALEH et al., "Cytochrome c and dATP-mediated Oligomerization of Apaf-1 Is a Prerequisite for Procaspase-9 Activation," J. Biol. Chem. 274:17941-17945 (1999)	
	36	SCHWARZE et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," Science 285:1569-1572 (1999)	
	37	STAPLETON et al., "The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization," Nature Structural Biology 6(1):44-49 (1999)	
	38	TATUSOVA et al., "Blast 2 Sequences, a new tool for comparing protein and nucleotide sequences," FEMS Microbiol Lett. 174:247-250 (1999)	
	39	THOME et al., "Identification of CARDIAK, a RIP-like kinase that associates with caspase-1," Curr. Biol. 8:885-888 (1998)	
	40	THORNBERRY., "Caspases: key mediators of apoptosis," Chemistry and Biology 5:R97-R103 (1998)	
	41	THORNBERRY et al., "A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes," Nature 356:768-774 (1992)	
	42	THORNBERRY et al., "Interleukin-1 beta converting enzyme: a novel cysteine protease required for IL-1 beta production and implicated in programmed cell death," Protein Sci. 4:3-12 (1995)	
	43	TSCHOPP et al., "Inhibition of Fas death signals by FLIPs," Curr. Op. Immunol. 10:552-558 (1998)	
	44	VAN DER BIEZEN et al., "The NB-ARC domain: a novel signalling [sic] motif shared by plant resistance gene products and regulators of cell death in animals," Curr. Biol. 8:R226-R227 (1998)	
	45	VOCERO-AKBANI et al., "Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein," Nature Med. 5:29-33 (1999)	
	46	WILLIS et al., "Bcl10 is Involved in the production of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types," Cell 96:35-45 (1999)	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
References were cited in previous application no.: 09/864,921

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. **066821-0267**	SERIAL NO. **10/766,682**
	APPLICANT **Reed, John C., et al.**	
	FILING DATE **January 27, 2004**	GROUP **1634**

	47	YUAN et al., "The Caenorhabditis elegans cell death gene ced-4 encodes a novel protein and is expressed during the period of extensive programmed cell death," Development 116:309-320 (1992)	
	48	ZOU et al., "Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c-Dependent Activation of Caspase-3," Cell 90:405-413 (1997)	
	49	ZOU et al., "An APAF-1·Cytochrome c Multimeric Complex is a Functional Apoptosome that Activates Procaspase-9," J. Biol. Chem. 274:11549-11556 (1999)	
	50	Database Accession No. AC007728	
	51	Database Accession No. AC010968	
	52	Database Accession No. AC010968	
	53	Database Accession No. AC025758	
	54	Database Accession No. AC026732	
	55	Database Accession No. AQ534686	
	56	GenBank: AC008810	
	57	GenBank: AC007728	
	58	GenBank: NT-002476	
	59	GenBank: AC010968	
	60	GenBank: AP001153	
	61	GenBank: AC022468	
	62	GenBank: AP000799 (withdrawn)	
	63	GenBank: AC023068	
	64	GenBank: W58453	
	65	GenBank: AA257158	
	66	GenBank: AA046000	
	67	GenBank: AW085161	
	68	GenBank: AI189838	
	69	GenBank: AA418021	
	70	GenBank: AA046105	
	71	GenBank: W58488	
	72	GenBank: AA418193	
	73	GenBank: AA257066	
	74	GenBank: BAA14061.1	
	75	GenBank: AP000658	
	76	Genbank: AQ309404	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
References were cited in previous application no.: 09/864,921